Lead Plaintiff Deadline: February 18, 2022
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
(1) the Food and Drug Administration had raised concerns regarding the validity of the clinical study designed to measure the efficacy and safety of bardoxolone for the treatment of chronic kidney disease caused by Alport syndrome; (2) as a result, there was a material risk that Reata’s New Drug Application would not be approved; and (3) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
In order to be included in the lawsuit, you must have incurred a loss on shares of Reata purchased or acquired during the class period listed above.
If you suffered a loss in Reata during the relevant time frame, you have until February 18, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.